Adrecizumab, given on top of standard of care, was well tolerated and showed a favorable safety profile Adrecizumab demonstrates a positive trend on survival AdrenOSS-2 is a biomarker-guided (sphingotest bio-ADM®[1]) trial in sepsis Mode of
Proof-of-concept Phase II trial AdrenOSS-2 is assessing first-in-class antibody Adrecizumab, designed to restore and maintain vascular integrity AdrenOSS-2 trial design and Adrecizumab mode of action will be presented at the European Society of Intensive Care
Hennigsdorf/Berlin (Germany), August 29, 2019 – Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is Chief Executive Officer (CEO)
Hennigsdorf (Germany), August 13, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the
Hennigsdorf (Germany), May 6, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at
AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients Proof-of-concept trial design testing Adrecizumab in early septic shock presented at International Symposium on Intensive Care
Hennigsdorf (Germany), March 12, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation in three upcoming conferences in Europe. Adrenomed representatives will be available for one-on-one meetings at these events. 12th
Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock Adrecizumab is a first-in-class antibody targeting Adrenomedullin, to rescue vascular function Vascular integrity, regulated by Adrenomedullin, is key to preventing vascular leakage and septic shock
For the second time, Adrenomed and sphingotec host international scientific symposium on vascular integrity in Berlin Top-tier clinical scientists and key opinion leaders discuss potential of Adrenomedullin in diagnosis and treatment of acute heart failure
Adrenomed AG, the vascular integrity company, today announced the closing of a EUR 24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors.
